Estudo randomizado | Tremelimumabe com durvalumabe em carcinoma hepatocelular irressecável.

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma – NEJM Evidence

Comentário no Twitter

Durvalumab plus a single dose of tremelimumab increased overall survival by just over 2.5 months in patients with unresectable hepatocellular carcinoma who had not received previous systemic therapy. Read more about the HIMALAYA trial by @GABOUALFA et al.: https://t.co/8d2qp54OLt pic.twitter.com/AA1RlSEP2a

— NEJM Evidence (@NEJMEvidence) June 6, 2022